Citizens JMP maintains $84 target on Rhythm Pharmaceuticals stock

Citizens JMP reaffirmed a Market Outperform rating for Rhythm Pharmaceuticals (RYTM) with an $84 price target, citing positive long-term setmelanotide data and the potential of its next-generation oral MC4R agonist, bivamelagon, despite a larger-than-expected Q1 2025 loss per share and revenue shortfall. Stifel analysts also raised their price target to $94, maintaining a Buy rating, driven by confidence in setmelanotide and its pipeline, especially following data presented at European congresses highlighting its effectiveness in hypothalamic obesity, with a supplemental New Drug Application planned for Q3 2025.

Analysis

Rhythm Pharmaceuticals (RYTM) presents a nuanced outlook, characterized by a recent Q1 2025 financial shortfall but buttressed by robust pipeline progress, strong analyst conviction, and strategic initiatives to highlight its niche market. The company reported a GAAP EPS of -$0.81 and revenue of $37.72 million for Q1 2025, missing consensus estimates, yet demonstrated a significant 45% year-over-year increase in net product revenues to $11.7 million, alongside impressive gross profit margins of 89.6%. Analyst sentiment remains notably positive, with four analysts recently revising earnings upward, Citizens JMP reaffirming a Market Outperform rating ($84 price target), and Stifel raising its target to $94 (Buy rating). This optimism is largely driven by the long-term data supporting setmelanotide's chronic use in indications like POMC/LEPR deficiency and Bardet-Biedl syndrome, and its planned supplemental New Drug Application for acquired hypothalamic obesity in Q3 2025. A critical upcoming catalyst is the Phase 2 data for the next-generation oral MC4R agonist, bivamelagon, expected next quarter; analysts view this as a significant, potentially underappreciated, value driver that could extend intellectual property by approximately 10 years. Rhythm, valued at $4.1 billion, is also actively engaging the medical community, for instance, through its upcoming product theater on rare neuro-endocrine diseases. The company's strong cash reserves provide a financial runway projected into 2027, supporting these development efforts.

Key Decisions for Investors

• Investors should prioritize monitoring upcoming catalysts, notably the Phase 2 data for bivamelagon due next quarter and the Q3 2025 sNDA submission for setmelanotide, as these are critical for future valuation.
• Evaluate the potential for value creation from bivamelagon, which analysts suggest may not be fully reflected in the current stock price, considering its promise of extended intellectual property and market opportunity.
• Carefully weigh the Q1 2025 earnings and revenue shortfall against the company's strong underlying net product revenue growth, robust gross margins, solid cash position through 2027, and consistent analyst support for its long-term strategy.